All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, How can we improve on current risk stratification in MDS?
How can we improve on current risk stratification in MDS?
In daily practice, the International Prognostic Scoring System (IPSS) and the revised IPSS are used for assessing prognosis and stratification of patients with MDS at diagnosis. However, in recent years, a lot of data have shown the impact of mutations in patients with MDS. Most of these mutations confer a poor prognosis when added to these risk stratification systems. Platzbecker underlines the importance of integrating these mutations into a holistic prognostication system, which should also include fatigue and patient-reported outcomes.
RIC allo-SCT vs HMA or best supportive care in older patients with high-risk MDS
The BMT CTN designed the phase II randomized trial 1102 (NCT02016781), to assess the benefits of reduced intensity conditioning (RIC) allo-SCT vs non-transplant...
Editorial theme | Genetic pathogenesis of MDS: Translating molecular advances into better diagnosis and prognosis of CCUS and MDS
The last 30 years of advances in molecular biology and high-throughput techniques have significantly impacted the...
Subscribe to get the best content related to MDS delivered to your inbox